# Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

> **NCT04959175** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 320 (estimated)

## Conditions studied

- Hematologic Neoplasms

## Interventions

- **DRUG:** Mycophenolate Mofetil
- **PROCEDURE:** Allogeneic HSCT
- **DRUG:** Fludarabine
- **DRUG:** Sirolimus
- **DRUG:** Filgrastim
- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **PROCEDURE:** Total Body Irradiation (TBI)

## Key facts

- **NCT ID:** NCT04959175
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-23
- **Primary completion:** 2027-04-27
- **Final completion:** 2027-04-30
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04959175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04959175, "Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04959175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*